Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.64 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783615 | 0.88 | KCNJ5 (0.65) | MAPTLMNATP53KCNJ5KCNJ3 | |
| SCHEMBL26546756 | 0.82 | KDR (0.76) | MAPTLMNATP53THRBKCNJ5 | |
| SCHEMBL3187383 | 0.81 | AR (0.55) | LMNAHTTNLRP3 | |
| SCHEMBL4582493 | 0.81 | MAPT (0.63) | MAPTLMNATP53THRBKCNJ5 | |
| SCHEMBL28884494 | 0.81 | KDR (0.69) | MAPTLMNATP53THRBKCNJ5 | |
| SCHEMBL15574146 | 0.81 | MAPT (0.61) | MAPTLMNATP53KCNJ5KCNJ3 | |
| SCHEMBL4443052 | 0.79 | KDR (0.71) | MAPTLMNATP53THRBKCNJ5 | |
| SCHEMBL13004812 | 0.79 | KDR (0.71) | MAPTLMNATP53THRBKCNJ5 | |
| SCHEMBL15687774 | 0.79 | KCNJ5 (0.63) | MAPTLMNATP53KCNJ5KCNJ3 | |
| SCHEMBL3197169 | 0.79 | MAPT (0.56) | MAPTLMNATP53KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | MAPT 3986/4885LMNA 4356/4885TP53 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.